Solvay Pharmaceuticals signs research agreement
Solvay Pharmaceuticals and Hormos Medical Corporation (Finland) have signed a research collaboration and license agreement in the women's health therapeutic area.
The agreement comprises a collaborative discovery programme, initially until January 2006 with possible extension beyond that. The agreement provides for a marriage between the special skills and insights Hormos has on molecules that can influence hormones, with the proven abilities of Solvay to develop and market women's health products successfully. Solvay strives to add therapies for the treatment of endometriosis and uterine fibroids to its portfolio of women's health products, and this research collaboration facilitates and helps to empower this ambition. Under the terms of the agreement the partners will collaborate in the generation, sharing and screening of compounds intended for development into future Solvay products. Solvay provides an annual research funding to Hormos during the collaboration, as well as milestone and royalty payments on compounds that are taken into product development.
Solvay Pharmaceuticals already has an important women's health franchise today, and is taking steps to secure a portfolio of future products in this area. The collaboration with Hormos constitutes a new and complementary addition to the research strategy for women's health in Solvay Pharmaceuticals, which includes a previously announced deal with Zentaris (Germany) on cetrorelix.
Other news from the department science
